Johnson & Johnson (JNJ)

It can provide some stability during volatile times.

Realty Income, Johnson & Johnson, and Chevron offer yields ranging from 2.2% to 5.1% in July 2026, supported by analyst buy ratings and institutional accumulation.

All three ETFs complement each other well in a portfolio.

As the megacap tech trade sputters, one attractive fund already owns what's leading instead -- and it's beating the market this year.

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

Abbott Labs could rally in a downturn and has a long-term growth catalyst to boot.

Johnson & Johnson stock makes good drugs, but it's valuation isn't great.

Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.

Johnson & Johnson is a healthcare giant, but an opportunity to invest in the United States and a plethora of big products suggest it still has growth appeal.

Their dividends are about as safe as they come.

Low-risk stocks are back in vogue.

Long-term investors should skip the SpaceX roller coaster, and pivot toward these three Dividend Kings instead.